Vtv Therapeutics Stock Today
| VTVT Stock | USD 13.50 0.10 0.74% |
Performance2 of 100
| Odds Of DistressOver 83
|
VTv Therapeutics is selling for under 13.50 as of the 11th of November 2024; that is 0.74 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 13.19. VTv Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for vTv Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of October 2024 and ending today, the 11th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2015 | Category Healthcare | Classification Health Care |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. The company has 2.43 M outstanding shares of which 28.96 K shares are at this time shorted by private and institutional investors with about 1.69 trading days to cover. More on vTv Therapeutics
Moving together with VTv Stock
| 0.61 | VANI | Vivani Medical Earnings Call Tomorrow | PairCorr |
Moving against VTv Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
VTv Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Paul MSc |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation | |
vTv Therapeutics (VTVT) is traded on NASDAQ Exchange in USA. It is located in 3980 Premier Drive, High Point, NC, United States, 27265 and employs 16 people. VTv Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.84 M. vTv Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.43 M outstanding shares of which 28.96 K shares are at this time shorted by private and institutional investors with about 1.69 trading days to cover.
vTv Therapeutics currently holds about 17.95 M in cash with (18.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Check VTv Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of VTv Therapeutics is $32.84 Million. vTv Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check VTv Ownership Details
VTv Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Planned Solutions, Inc. | 2024-09-30 | 25.0 | |
| Cornerstone Planning Group Llc | 2024-06-30 | 19.0 | |
| Sunbelt Securities | 2024-06-30 | 15.0 | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 9.0 | |
| Bank Of America Corp | 2024-06-30 | 8.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 2.0 | |
| Qube Research & Technologies | 2024-06-30 | 1.0 | |
| Royal Bank Of Canada | 2024-06-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Samsara Biocapital, Llc | 2024-06-30 | 206.8 K | |
| Baker Bros Advisors Lp | 2024-06-30 | 97.3 K |
vTv Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. VTv Therapeutics market risk premium is the additional return an investor will receive from holding VTv Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.023 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.76) | |||
| Sortino Ratio | (0.02) |
VTv Stock Against Markets
VTv Therapeutics Corporate Management
| David III | Sr Counsel | Profile | |
| Vanessa McDade | Chief Officer | Profile | |
| Elizabeth Keiley | Executive Counsel | Profile | |
| Carmen Valcarce | Chief VP | Profile | |
| MD FACC | Executive Chairperson | Profile |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.